Report: Sanofi-Aventis may shorten name
NEW YORK — French drug maker Sanofi-Aventis may get a name change soon, according to a published report.
Bloomberg reported that the drug maker had scheduled a vote at its May 6 stockholders meeting to shorten the name to “Sanofi.” The article paraphrased a spokesman as saying that the current name is difficult for people in some countries to pronounce.
The Sanofi-Aventis name came into being following the 2004 acquisition of Aventis by Sanofi-Synthelabo.
Many publications, including Drug Store News, already use “Sanofi” as an abbreviated form of the company’s name.
Sanofi-Aventis completes Genzyme acquisition
PARIS — Sanofi-Aventis said it completed its exchange offer for drug maker Genzyme, which expired just before midnight April 1.
All 224,528,469 shares of Genzyme common stock were validly tendered, which is represented by 84.6% of common stock and 77% of shares on a diluted basis.
Last month, the board of directors of Genzyme unanimously recommended that shareholders accept French drug maker Sanofi-Aventis’ $74-per-share buyout offer.
Daiichi Sankyo appoints new CEO
PARSIPPANY, N.J. — Daiichi Sankyo’s SVP commercial operations has taken on a new role at the company.
The drug maker said that John Gargiulo would become president and CEO, effective Monday, following the retirement of current leader Joseph Pieroni.
Gargiulo has been with Daiichi Sankyo since its inception in 1996. In addition to his role at the company, he currently serves on the board of directors of the Pharmaceutical Research and Manufacturers Association, as well as the National Pharmaceutical Council.
"I am excited about leading DSI through our next company milestones and fostering a continuing vision of employee excellence that will drive DSI growth and success," Gargiulo said.